Benefits and side effects of cyclosporine a 0.05% eye drops in dry eye diseases
Abstract
Objectives- To know the effect of topical cyclosporine A 0.05% eye drops in dry eye disease and evaluate its side effects.
Materials and methods- 30 cases, above age of15 year, of dry eye syndrome were included. Grading were doneas following eight symptoms, chronic sandy-gritty irritation, persistent dryness, foreign body sensation, scratching and burning, watery eyes, photophobia, itching and transient blurring of vision. The signs noted in cases of dry eye are tear breakup time and schirmer value. Cyclosporine A 0.05% ophthalmic emulsioneye drop used 12 hourly. Follow up of patients on after 15 days, every month for 3 months then after 6 months.
Results- In 30 cases, malefemale ratio were 5:1. According tosymptoms, 50% mild, 30% moderate and 20% were severe, andaccording to signs 46.66%mild,33.33% moderate, and 20.00% were severe. After cyclosporine a treatment 20 became normal, 8 partially improved and 2 no improvement in symptoms while 20 became normal, 9 partially improved and1patient showed no improvement in signs. Local side effect likeburningin 23.33%, discharge in 60.66%, foreign body sensation in 13.33%, stinging in 13.33%, conjuctival hyperemia in 20% and visual disturbance in 6% eyes.
Conclusions- Topical cyclosporine A 0.05% eye drop twice daily in dry eye diseases improve symptom as well as signs (schirmer”s value and tear breakup time) with minimal tolerable local side effects.
Downloads
References
2. O’Brien, Collum LM. Dry eye: diagnosis and current treatment strategies. Curr Allergy Asthma Rep. 2004;4 (4): 314–319.
3. Foulks GN, Forstot SL, Donshik PC, et al. Clinical guidelines for management of dry eye associated with Sjögren disease. Ocul Surf. 2015; 13 (2):118– 32.
4. Shin MS, Kim JI, Lee MS, et al. Acupuncture for treating dry eye: randomized placebo-controlled trial. Acta Ophthalmol. 2010;88(8): e328–e333.
5. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002;25(1):33–55.
6. Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005; 112(10):1790–1794.
7. Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol. 2008;126(8):1046– 1050
Copyright (c) 2017 Author (s). Published by Siddharth Health Research and Social Welfare Society
This work is licensed under a Creative Commons Attribution 4.0 International License.